National Jewish Health has a tremendous clinical research program whose investigators seek to systematically advance understanding of interstitial lung disease (ILD), including its epidemiology, natural history, and prognosis. There is particular emphasis on developing or identifying patient-reported outcome measures to assess the impact of pharmacological and non-pharmacological therapeutic interventions on patients, and to broadly assess how living with ILD affects patients’ quality of life.
National Jewish Health has a repository of biological specimens from more than 200 ILD patients seen at National Jewish Health. By cross-referencing these samples with our EMR, we are able to identify highly relevant samples derived from clinical information collected over time, including laboratory testing, symptoms, diagnoses and demographics.
ILD Clinical Trials
National Jewish Health conducts both industry-sponsored and NIH-funded Phase I – Phase IV clinical trials. Our team has extensive experience managing all aspects of clinical trials, including:
- Study design
- Patient recruitment
- Clinical monitoring
- Regulatory compliance